Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -18.39% is 65% above its 5-year average of -52.14%, near the high end of its 5-year range (-99.30%–-18.39%).
72.09% above its 12-month average of -65.88%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -19.50%.
RETURN ON ASSETS (ROA)
-18.39%
RETURN ON ASSETS (ROA) AVG TTM
-65.88%
RETURN ON ASSETS (ROA) AVG 3Y
-62.81%
RETURN ON ASSETS (ROA) AVG 5Y
-52.14%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+72.09%
CURRENT VS 3Y AVG
+70.72%
CURRENT VS 5Y AVG
+64.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+42.96%
vs the sector median at left
HCW Biologics Inc.
Market Cap
$561440.00
Return on Assets (ROA)
-18.39%
TTM Avg
-65.88%
3Y Avg
-62.81%
5Y Avg
-52.14%
Market Cap
$518863.00
Return on Assets (ROA)
-320.72%
TTM Avg
-102.20%
3Y Avg
-130.11%
5Y Avg
-99.50%
Market Cap
$492926.00
Return on Assets (ROA)
-60.68%
TTM Avg
-88.11%
3Y Avg
-75.03%
5Y Avg
-60.97%
Market Cap
$694041.00
Return on Assets (ROA)
2.60%
TTM Avg
-212.84%
3Y Avg
-24543.27%
5Y Avg
-19977.79%
Market Cap
$403887.00
Return on Assets (ROA)
-7.29%
TTM Avg
-16.88%
3Y Avg
-23.60%
5Y Avg
-32.13%
Market Cap
$747565.00
Return on Assets (ROA)
N/A
TTM Avg
-16.55%
3Y Avg
-16.64%
5Y Avg
-15.27%
Market Cap
$355726.00
Return on Assets (ROA)
-60.35%
TTM Avg
-77.33%
3Y Avg
-83.27%
5Y Avg
-755.53%
Market Cap
$814420.00
Return on Assets (ROA)
N/A
TTM Avg
7.00%
3Y Avg
-3.42%
5Y Avg
-4.05%
Market Cap
$829870.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $561440.00 | -18.39% | -65.88% | -62.81% | -52.14% |
| VivoSim Labs, Inc. (VIVS)vs › | $518863.00 | -320.72% | -102.20% | -130.11% | -99.50% |
| XORTX Therapeutics Inc. (XRTX)vs › | $492926.00 | -60.68% | -88.11% | -75.03% | -60.97% |
| CDT Equity Inc. (CDT)vs › | $694041.00 | 2.60% | -212.84% | -24543.27% | -19977.79% |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | -7.29% | -16.88% | -23.60% | -32.13% |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $747565.00 | N/A | -16.55% | -16.64% | -15.27% |
| Virax Biolabs Group Limited (VRAX)vs › | $355726.00 | -60.35% | -77.33% | -83.27% | -755.53% |
| Ridgetech, Inc. (RDGT)vs › | $814420.00 | N/A | 7.00% | -3.42% | -4.05% |
| Decoy Therapeutics Inc. (DCOY)vs › | $829870.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $836773.00 | -63.04% | -106.06% | -121.33% | -96.21% |
ROA
-18.4%
ROE
-66.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -32.46% |
| 2024-12-31 | -99.30% |
| 2023-12-31 | -87.66% |
| 2022-12-31 | -31.83% |
| 2021-12-31 | -24.04% |
| 2020-12-31 | -37.54% |
| 2019-12-31 | -72.45% |
